Protalix BioTherapeutics
PLX
PLX
36 hedge funds and large institutions have $3.47M invested in Protalix BioTherapeutics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
58% less capital invested
Capital invested by funds: $8.2M → $3.47M (-$4.73M)
73% less call options, than puts
Call options by funds: $22K | Put options by funds: $81K
Holders
36
Holding in Top 10
–
Calls
$22K
Puts
$81K
Top Buyers
| 1 | +$136K | |
| 2 | +$38.4K | |
| 3 | +$8.91K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.11K |
| 5 |
Jane Street
New York
|
+$6.68K |
Top Sellers
| 1 | -$221K | |
| 2 | -$156K | |
| 3 | -$22K | |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21.8K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$4.37K |